Pure Biologics – From a Bootstrapped Boutique CRO to an Integrated Drug Discovery Public Company

Sameer	      Deshmukh; Przemysław	      Jurek; Filip	      Jelen; Sabina	      Tabaczar; Tomasz	      Bakowski; David	      Carter; Richard	      Fox; Marta	      Wawrzyniak; Maciej	   P.   Mazurek

doi:10.2174/2213809907666200313114152

Abstract

The present article is a case study of a Polish biopharmaceutical company, “Pure Biologics”. The company was founded in 2010 by a group of scientists and, over the last nine years, grew substantially from just a few individuals to nearly one hundred professionals. Initially, a privately-funded civil partnership, Pure Biologics, has been transformed into a publicly-traded company. Such a transformation has been possible not only because of the expertise and growing experience of corporate management, but also the specific economic environment and substantial public funding dedicated to innovative Small and Medium Enterprises (SMEs).

Keywords: Small and Medium Enterprises (SMEs), immuno-oncology, Polish biopharmaceutical companies, therapeutic medical devices, aptamers, bispecific antibodies.

« Previous Next »

[1] 
Jakovljevic M, Camilleri C, Rancic N, et al. Cold War Legacy in Public and Private Health Spending in Europe. Public Health Front  2018; 6: 215.
[http://dx.doi.org/10.3389/fpubh.2018.00215] [PMID: 30128309] 
[2] 
Deacon B. Eastern European welfare states: the impact of the politics of globalization. J Eur Soc Policy  2000; 10(2): 146-61.
[http://dx.doi.org/10.1177/a012487] 
[3] 
Robbins PT, Huzair F, Eds. Exploring central and eastern Europe’s biotechnology landscape.  Dordrecht: Springer Netherlands 2012; pp. 1-11.
[http://dx.doi.org/10.1007/978-90-481-9784-2] 
[4] 
Tyl M, Meissner Z, Mosedale C. Polish Biotech: landscape & opportunities Available from:. https://impactcee.com/wp-content/uploads/2018/09/ Impact_Report_Biotech-1.pdf
[5] 
Pure biologics Available from:. http://purebiologics.com
[6] 
Nixon AE, Sexton DJ, Ladner RC. Drugs derived from phage display: from candidate identification to clinical practice. MAbs  2014; 6(1): 73-85.
[http://dx.doi.org/10.4161/mabs.27240] [PMID: 24262785] 
[7] 
Zhang Y, Lai BS, Juhas M. Recent advances in aptamer discovery and applications. Molecules  2019; 24(5): 941.
[http://dx.doi.org/10.3390/molecules24050941] [PMID: 30866536] 
[8] 
Jurek P, Matusiewicz M, Mazurek M, Jelen F. In chemico modification of nucleotides for better recognition.Aptamers for analytical applications.  Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA 2018; pp. 27-84.
[http://dx.doi.org/10.1002/9783527806799.ch2] 
[9] 
Pharmaceutical and biotechnological sector in poland polish information and foreign investment agency  2010.Available from:. https://www.paih.gov.pl/files/ ?id_plik=19608
[10] 
Kowalak B. Benchmarking of technological parks in Poland - report for 2010 Polish agency for enterprise development 2010.Available from:. https:// bip.parp.gov.pl/storage/publications/pdf/2010_bench _tech_raport_ogolny_en.pdf
[11] 
The National Centre for Research and Development Available from:. https://www.ncbr.gov.pl/en/
[12] 
DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ  2016; 47: 20-33.
[http://dx.doi.org/10.1016/j.jhealeco.2016.01.012] [PMID: 26928437] 
[13] 
Minter R. phage display - a practical approach. Brief Funct Genomics Proteomics  2005; 3(4): 391-2.
[http://dx.doi.org/10.1093/bfgp/3.4.391] 
[14] 
Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science  1985; 228(4705): 1315-7.
[http://dx.doi.org/10.1126/science.4001944] [PMID: 4001944] 
[15] 
Frenzel A, Kügler J, Helmsing S, et al. Designing human antibodies by phage display. Transfus Med Hemother  2017; 44(5): 312-8.
[http://dx.doi.org/10.1159/000479633] [PMID: 29070976] 
[16] 
Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science  1990; 249(4968): 505-10.
[http://dx.doi.org/10.1126/science.2200121] [PMID: 2200121] 
[17] 
Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature  1990; 346(6287): 818-22.
[http://dx.doi.org/10.1038/346818a0] [PMID: 1697402] 
[18] 
Jurek P, Jelen F, Mazurek M, Jakimowicz P. Method of synthesis and purification of a nucleoside and/or a nucleotide, a modified nucleoside and/or nucleotide, a DNA molecule and an oligonucleotide library comprising said modified nucleoside and/or nucleotide and the use of said oligonucleotide library US Patent 10450673.. 
[19] 
Pure biologics Pure Apta platform Available from:. http://purebiologics.pl/en/r-and-d/technology-platforms/pureapta/
[20] 
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell  2011; 144(5): 646-74.
[http://dx.doi.org/10.1016/j.cell.2011.02.013] [PMID: 21376230] 
[21] 
Lake RA, Robinson BWS. Immunotherapy and chemotherapy: a practical partnership. Nat Rev Cancer  2005; 5(5): 397-405.
[http://dx.doi.org/10.1038/nrc1613] [PMID: 15864281] 
[22] 
Colorectal Cancer Facts & Figures 2017-2019 American cancer society Available from:. https://www.cancer.org/content/dam/cancer-org/research/ cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/ colorectal-cancer-facts-and-figures-2017-2019.pdf
[23] 
Koyama S, Akbay EA, Li YY, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun  2016; 7(1): 10501.
[http://dx.doi.org/10.1038/ncomms10501] [PMID: 26883990] 
[24] 
Goel G, Sun W. Cancer immunotherapy in clinical practice: the past, present, and future. Chin J Cancer  2014; 33(9): 445-57.
[http://dx.doi.org/10.5732/cjc.014.10123] [PMID: 25189717] 
[25] 
Wayteck L, Breckpot K, Demeester J, De Smedt SC, Raemdonck K. A personalized view on cancer immunotherapy. Cancer Lett  2014; 352(1): 113-25.
[http://dx.doi.org/10.1016/j.canlet.2013.09.016] [PMID: 24051308] 
[26] 
Chaudhuri D, Suriano R, Mittelman A, Tiwari RK. Targeting the immune system in cancer. Curr Pharm Biotechnol  2009; 10(2): 166-84.
[http://dx.doi.org/10.2174/138920109787315114] [PMID: 19199949] 
[27] 
Leone P, Shin E-C, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst  2013; 105(16): 1172-87.
[http://dx.doi.org/10.1093/jnci/djt184] [PMID: 23852952] 
[28] 
Bakker ABH, Wu J, Phillips JH, Lanier LL. NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Hum Immunol  2000; 61(1): 18-27.
[http://dx.doi.org/10.1016/S0198-8859(99)00160-3] [PMID: 10658974] 
[29] 
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med  2010; 363(20): 1938-48.
[http://dx.doi.org/10.1056/NEJMra1001389] [PMID: 21067385] 
[30] 
Triple-negative breast cancer 2019.Available from:. https://www.breastcancer.org/symptoms/diagnosis/trip_neg
[31] 
Aranda F, Vacchelli E, Eggermont A, et al. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. OncoImmunology  2014; 3(1)e27297
[http://dx.doi.org/10.4161/onci.27297] [PMID: 24701370] 
[32] 
Lim E, Palmieri C, Tilley WD. Renewed interest in the progesterone receptor in breast cancer. Br J Cancer  2016; 115(8): 909-11.
[http://dx.doi.org/10.1038/bjc.2016.303] [PMID: 27657336] 
[33] 
Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract  2012; 2012743193
[http://dx.doi.org/10.1155/2012/743193] [PMID: 23320171] 
[34] 
Prijatel P. You can survive triple negative 2011.Available from: . https://community. breastcancer.org/ blog/you-can-survive-triple-negative/
[35] 
Women And Health: Today’s Evidence - Tomorrow’s Agenda World Health Organization (WHO) 2009.Available from:. https://apps.who.int/iris/bitstream/ handle/10665/44168/9789241563857_eng.pdf
[36] 
The cancer atlas The American Cancer Society, inc 2018.Available from:. https://canceratlas.cancer.org/ wp-content/uploads/2019/09/CA3_Europe.pdf
[37] 
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer  2018; 103: 356-87.
[http://dx.doi.org/10.1016/j.ejca.2018.07.005] [PMID: 30100160] 
[38] 
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol  2016; 13(11): 674-90.
[http://dx.doi.org/10.1038/nrclinonc.2016.66] [PMID: 27184417] 
[39] 
Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: the seventh special issue. J Clin Apher  2016; 31(3): 149-62.
[http://dx.doi.org/10.1002/jca.21470] [PMID: 27322218] 
[40] 
Daga RD, Miguel FS, González-de-Molina FJ, Úbeda-Iglesias A, Pérez AN, Forés RJ. Plasmapheresis and other extracorporeal filtration techniques in critical patients. Med Intensiva  2017; 41(3): 174-87.
[http://dx.doi.org/10.1016/j.medin.2016.10.005] [PMID: 28062169] 
[41] 
Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology  2016; 87(4): 419-25.
[http://dx.doi.org/10.1212/WNL.0000000000002790] [PMID: 27358333] 
[42] 
Romeo AR, Segal BM. Treatment of neuromyelitis optica spectrum disorders. Curr Opin Rheumatol  2019; 31(3): 250-5.
[http://dx.doi.org/10.1097/BOR.0000000000000603] [PMID: 30920972] 
[43] 
Filipov JJ, Zlatkov BK, Dimitrov EP. Plasma exchange in clinical practice plasma medicine - concepts and clinical applications. InTech 2018.
[http://dx.doi.org/10.5772/intechopen.76094] 
[44] 
Marignier R, Cobo Calvo A, Vukusic S. Neuromyelitis optica and neuromyelitis optica spectrum disorders. Curr Opin Neurol  2017; 30(3): 208-15.
[http://dx.doi.org/10.1097/WCO.0000000000000455] [PMID: 28306572] 
[45] 
Gilhus NE. Myasthenia Gravis. N Engl J Med  2016; 375(26): 2570-81.
[http://dx.doi.org/10.1056/NEJMra1602678] 
[46] 
Miller KL, Lanthier M. Investigating the landscape of US orphan product approvals. Orphanet J Rare Dis  2018; 13(1): 183.
[http://dx.doi.org/10.1186/s13023-018-0930-3] [PMID: 30348193] 
[47] 
Micklus A, Muntner S. Biopharma dealmaking in 2018. Nat Rev Drug Discov  2019; 18(2): 93-4.
[http://dx.doi.org/10.1038/d41573-019-00013-y] [PMID: 30710140] 
[48] 
Piper N, Cartwright H, Taskin A. deal trends in immuno-oncology IQVIA 2018.Available from:. https://www.iqvia.com/Library/White-Papers/Deal-Trend-in-Immuno-oncology
[49] 
Yip S. Top 10 best-selling drugs of 2018 fund US and EU pharma R&D  Pharma intelligence 2019.Available from:. https://pharmaintelligence.informa.com/ ~/media/informa-shop-window/pharma/2019/files/ whitepapers/top-10-best-selling-drugs-of-2018-fund-us-and-eu-pharma-rd.pdf

Rights & Permissions Print Cite

Article Metrics

12

1

DOI https://dx.doi.org/10.2174/2213809907666200313114152	Print ISSN 2213-8099
Publisher Name Bentham Science Publisher	Online ISSN 2213-8102

Technology Transfer and Entrepreneurship (Discontinued)

Pure Biologics – From a Bootstrapped Boutique CRO to an Integrated Drug Discovery Public Company

Abstract